ProQR Therapeutics (PRQR) Competitors $2.56 -0.02 (-0.78%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.57 +0.01 (+0.55%) As of 02/21/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends PRQR vs. NUVB, PRTA, CRON, GHRS, BCAX, VERV, MNMD, DNTH, AVXL, and OPTShould you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Nuvation Bio (NUVB), Prothena (PRTA), Cronos Group (CRON), GH Research (GHRS), Bicara Therapeutics (BCAX), Verve Therapeutics (VERV), Mind Medicine (MindMed) (MNMD), Dianthus Therapeutics (DNTH), Anavex Life Sciences (AVXL), and Opthea (OPT). These companies are all part of the "pharmaceutical products" industry. ProQR Therapeutics vs. Nuvation Bio Prothena Cronos Group GH Research Bicara Therapeutics Verve Therapeutics Mind Medicine (MindMed) Dianthus Therapeutics Anavex Life Sciences Opthea ProQR Therapeutics (NASDAQ:PRQR) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends. Do insiders and institutionals hold more shares of PRQR or NUVB? 32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 5.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, PRQR or NUVB? ProQR Therapeutics has higher revenue and earnings than Nuvation Bio. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProQR Therapeutics$7.05M29.66-$30.43M-$0.32-8.00Nuvation BioN/AN/A-$75.80M-$2.17-1.02 Do analysts rate PRQR or NUVB? ProQR Therapeutics presently has a consensus target price of $8.83, suggesting a potential upside of 245.05%. Nuvation Bio has a consensus target price of $8.20, suggesting a potential upside of 271.88%. Given Nuvation Bio's higher possible upside, analysts clearly believe Nuvation Bio is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in PRQR or NUVB? ProQR Therapeutics received 284 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 80.00% of users gave Nuvation Bio an outperform vote while only 61.71% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformProQR TherapeuticsOutperform Votes33261.71% Underperform Votes20638.29% Nuvation BioOutperform Votes4880.00% Underperform Votes1220.00% Is PRQR or NUVB more profitable? Nuvation Bio has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. Nuvation Bio's return on equity of -21.89% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ProQR Therapeutics-134.31% -71.58% -19.70% Nuvation Bio N/A -21.89%-17.86% Which has more risk & volatility, PRQR or NUVB? ProQR Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Does the media refer more to PRQR or NUVB? In the previous week, ProQR Therapeutics and ProQR Therapeutics both had 2 articles in the media. Nuvation Bio's average media sentiment score of 0.97 beat ProQR Therapeutics' score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNuvation Bio beats ProQR Therapeutics on 9 of the 16 factors compared between the two stocks. Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRQR vs. The Competition Export to ExcelMetricProQR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$210.74M$7.05B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-8.006.1126.7419.18Price / Sales29.66268.29435.4670.76Price / CashN/A65.6738.0134.83Price / Book4.656.707.644.62Net Income-$30.43M$138.98M$3.19B$246.06M7 Day Performance5.79%-2.63%-2.12%-2.63%1 Month Performance14.80%-2.33%-0.45%-2.15%1 Year Performance26.11%-5.33%16.26%12.88% ProQR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRQRProQR Therapeutics1.9524 of 5 stars$2.56-0.8%$8.83+245.1%+34.7%$210.74M$7.05M-8.00180NUVBNuvation Bio2.0445 of 5 stars$2.28-0.7%$8.20+260.4%+23.9%$765.70MN/A-1.0560PRTAProthena3.125 of 5 stars$14.17+2.0%$46.50+228.2%-42.5%$762.49M$91.37M-5.71130Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpCRONCronos Group1.2635 of 5 stars$1.97-1.5%$3.00+52.3%-10.0%$753.58M$87.24M-15.15450GHRSGH Research2.5113 of 5 stars$14.31flat$30.25+111.4%+62.2%$744.52MN/A-18.1110Gap UpBCAXBicara TherapeuticsN/A$13.48+2.7%$41.20+205.6%N/A$733.58MN/A0.0032VERVVerve Therapeutics2.921 of 5 stars$8.58+11.3%$25.75+200.1%-44.6%$726.42M$24.40M-3.49110Upcoming EarningsAnalyst ForecastMNMDMind Medicine (MindMed)2.1419 of 5 stars$9.89+14.3%$26.33+166.3%+65.2%$725.25MN/A-4.3840Gap UpHigh Trading VolumeDNTHDianthus Therapeutics1.7679 of 5 stars$24.49+1.5%$46.83+91.2%-1.3%$724.90M$2.83M-9.8080AVXLAnavex Life Sciences3.7896 of 5 stars$8.52+0.6%$44.00+416.4%+64.4%$722.67MN/A-16.3840Analyst ForecastAnalyst RevisionGap UpOPTOpthea2.0626 of 5 stars$5.21+1.0%$12.00+130.3%+46.8%$710.80M$120,000.000.008Upcoming Earnings Related Companies and Tools Related Companies Nuvation Bio Competitors Prothena Competitors Cronos Group Competitors GH Research Competitors Bicara Therapeutics Competitors Verve Therapeutics Competitors Mind Medicine (MindMed) Competitors Dianthus Therapeutics Competitors Anavex Life Sciences Competitors Opthea Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRQR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
